Recent advances in the synthesis and biological activity studies of pyridine and pyrimidine derivatives: A review

References (112)

1. [1] Wang S, Bao L, Song D, Wang J, Cao X. “Heterocyclic lactam derivatives containing piperonyl moiety as potential antifungal agents”. Bioorganic & Medicinal Chemistry Letters, 29(20), 126661, 2019.
2. [2] Korol N, Molnar-Babilya D, Slivka M, Onysko M. “A brief review on heterocyclic compounds with promising antifungal activity against Candida species”. Organic Communications, 15(4), 304-323, 2022.
3. [3] Muslim RF, Owaid MN. “Synthesis, characterization and evaluation of the anti-cancer activity of silver nanoparticles by natural organic compounds extracted from cyperus sp. rhizomes”. ACTA Pharmaceutica Sciencia, 57(2), 129, 2019.
4. [4] Yang L, Bo Xu W, Sun L, Zhang, C, Hua Jin C. “SAR analysis of heterocyclic compounds with monocyclic and bicyclic structures as antifungal agents”. ChemMedChem, 17(12) e202200221, 2022.
5. [5] Mermer A, Keles, T, Sirin Y. “Recent studies of nitrogen containing heterocyclic compounds as novel antiviral agents: A review”. Bioorganic Chemistry, 114, 105076, 2021.
6. [6] Negi M, Chawla PA, Faruk A, Chawla V. “Role of heterocyclic compounds in SARS and SARS CoV-2 pandemic”. Bioorganic Chemistry, 104, 104315, 2020.
7. [7] Borchers, A, Pieler, T. “Programming pluripotent precursor cells derived from Xenopus embryos to generate specific tissues and organs”. Genes (Basel), 1(3), 413-26, 2010.
8. [8] Wang SB, Liu H, Li GY, Li J, Li XJ, Lei K, Liu RM. “Coumarin and 3,4-dihydroquinolinone derivatives: Synthesis, antidepressant activity, and molecular docking studies”. Pharmacological Reports, 71(6),1244-1252, 2019.
9. [9] Kim JY, Kim D, Kang SY, Park WK, Kim HJ, Jung ME, Lee J. “Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant”. Bioorganic & Medicinal Chemistry Letters 20(22), 6439-42, 2010.
10. [10] Singh K, Pal R, Khan SA, Kumar B, Akhtar MJ. “Insights into the structure activity relationship of nitrogen-containing heterocyclics for the development of antidepressant compounds: An updated review”. Journal of Molecular Structure, 1237, 130369, 2021.
11. [11] Akhtar J, Khan, AA, Ali Z, Haider R, Yar MS. “Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities”. European Journal of Medicinal Chemistry, 125, 143-189, 2017.
12. [12] Mirza AZ. “Advancement in the development of heterocyclic nucleosides for the treatment of cancer-a review”. Nucleosides Nucleotides Nucleic Acids, 38(11), 836-857, 2019.
13. [13] Sharma S, Kumar D, Singh G, Monga V, Kumar B. “Recent advancements in the development of heterocyclic anti-inflammatory agents”. European Journal of Medicinal Chemistry, 200, 112438, 2020.
14. [14] Wei ZY, Chi KQ, Wang KS, Wu J, Liu LP, Piao HR “Design, synthesis, evaluation, and molecular docking of ursolic acid derivatives containing a nitrogen heterocycle as anti-inflammatory agents”. Bioorganic & Medicinal Chemistry Letters, 28(10), 1797-1803, 2018.
15. [15] Abubakar S, Khairuddean M, Ismail N Z, Salhimi SM, Al-Amin M, Wahyuningsih TD. “Synthesis and computational insights of hybrid heterocyclic bis-chalcone compounds and their cytotoxic effects against breast cancer cells”. Results in Chemistry, 7, 101464, 2024.
16. [16] Albratty M, Alhazm HA. “Novel pyridine and pyrimidine derivatives as promising anticancer agents: A review”. Arabian Journal of Chemistry, 15(6), 103846, 2022.
17. [17] Borah B, Banerjee S, Allam BK “Recent Advances in the Catalytic Applications of Tin Dioxide-Based Materials in the Synthesis of Bioactive Heterocyclic Compounds”. Tetrahedron Green Chem, 4, 100048, 2024.
18. [18] Macit AZ, Hasanoğlu Özkan E, Ogutcu H, Nartop D. “Nartop, synthesis and in vitro antimicrobial evaluation of novel potent bioactive heterocyclic compounds”. Polycyclic Aromatic Compounds, 44(10), 6862-6873, 2024.
19. [19] Masaret, GS. “New Potential Antitumor Pyrimidine Derivatives: Synthesis and Cytotoxicity Evaluation”. Polycyclic Aromatic Compounds, 42(8), 5336-5351, 2022.
20. [20] Savcı A, Turan N, Buldurun K, Alkış M E, Alan Y. “Schiff base containing fluorouracil and its M (II) complexes: Synthesis, characterization, cytotoxic and antioxidant activities”. Inorganic Chemistry Communications, 143, 109780, 2022.
21. [21] Savcı A, Buldurun K, Kırkpantur G. “A new Schiff base containing 5-FU and its metal Complexes: Synthesis, Characterization, and biological activities”. Inorganic Chemistry Communications, 134, 109060, 2021.
22. [22] Buldurun K, Turan N, Aras A, Mantarcı A, Turkan F, Bursal E. “Spectroscopic and structural characterization, enzyme inhibitions, and antioxidant effects of new Ru (II) and Ni (II) complexes of Schiff base”. Chemistry & biodiversity, 16(8), e1900243, 2019.
23. [23] Buldurun K, Turan N, Savci A, Alan Y, Colak N. “Synthesis, characterization, X-ray diffraction analysis of a tridentate Schiff base ligand and its complexes with Co (II), Fe (II), Pd (II) and Ru (II): Bioactivity studies”. Iran. J. Chem. Chem. Eng. Research, 41(8), 2635-2649, 2022.
24. [24] Ibarra-Rodríguez M, Muñoz-Flores B M, Dias H R, Sanchez M, Gomez-Trevino A, Santillan R, Farfán N, Jimenez-Perez VM. “Fluorescent molecular rotors of organoboron compounds from schiff bases: synthesis, viscosity, reversible thermochromism, cytotoxicity, and bioimaging cells”. The Journal of Organic Chemistry, 82(5), 2375-2385, 2017.
25. [25] Goshisht M K, Patra G K, Tripathi N. “Fluorescent Schiff base sensors as a versatile tool for metal ion detection: strategies, mechanistic insights, and applications”. Materials Advances, 3(6), 2612-2669, 2022.
26. [26] Kagatikar S, Sunil D. “Schiff bases and their complexes in organic light emitting diode application”. Journal of Electronic Materials, 50(12), 6708-6723, 2021.
27. [27] Buldurun K, Tanış E, Turan N, Çolak N, Çankaya N. “Solvent effects on the electronic and optical properties of Ni (II), Zn (II), and Fe (II) complexes of a Schiff base derived from 5-bromo-2-hydroxybenzaldehyde”. Journal of Chemical Research, 45(7-8), 753-759, 2021.
28. [28] Jeevadason AW, Murugavel KK, Neelakantan M A. “Review on Schiff bases and their metal complexes as organic photovoltaic materials”. Renewable and Sustainable Energy Reviews, 36, 220-227, 2014.
29. [29] El‐Remaily MAEAAA, El‐Dabea T, El‐Khatib RM, Abdou A, El Hamd MA, Abu‐Dief AM. “Efficiency and development of guanidine chelate catalysts for rapid and green synthesis of 7‐amino‐4, 5‐dihydro‐tetrazolo [1,5‐a] pyrimidine‐6‐carbonitrile derivatives supported by density functional theory (DFT) studies”. Applied Organometallic Chemistry, 37(11), e7262, 2023.
30. [30] HM P, Khanum SA “An Overview of the Synthetic Routes and Pharmacological Aspects of Pyridine, Isoxazole, Thiazole, and Indole Derivatives”. Polycyclic Aromatic Compounds, 44(10), 7168-7196, 2023.
31. [31] Abdel-Megeed MF, Badr BE, Azaam M M, El-Hiti G A. “Synthesis, antimicrobial and anticancer activities of a novel series of diphenyl 1-(pyridin-3-yl)ethylphosphonates”. Bioorganic & Medicinal Chemistry, 20(7), 2252-2258, 2012.
32. [32] Shukla NM, Salunke DB, Yoo E, Mutz CA, Balakrishna R, David SA. “Antibacterial activities of Groebke-Blackburn-Bienayme-derived imidazo [1,2-a]pyridin-3-amines”. Bioorganic & Medicinal Chemistry, 20(19), 5850-5863, 2012.
33. [33] Jardosh HH, Patel MP “Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents”. European Journal of Medicinal Chemistry, 65, 348-359, 2013.
34. [34] Kim HS, Jadhav JR, Jung SJ, Kwak JH. “Synthesis and antimicrobial activity of imidazole and pyridine appended cholestane-based conjugates”. Bioorganic & Medicinal Chemistry Letters, 23(15), 4315-4318, 2013.
35. [35] Jose G, Suresha Kumara, TH Nagendrappa G, Sowmya HB, Jasinski JP, Millikan SP, Chandrika N, More SS, Harish BG. “New polyfunctional imidazo [4,5-c]pyridine motifs: synthesis, crystal studies, docking studies and antimicrobial evaluation”. European Journal of Medicinal Chemistry, 77, 288-97, 2014.
36. [36] Jose G, Suresha Kumara TH, Nagendrappa G, Sowmya HBV, Jasinski JP, Millikan SP, More SS, Janardhan B, Harish BG, Chandrika N. “Synthesis, crystal structure, molecular docking and antimicrobial evaluation of new pyrrolo [3,2-c]pyridine derivatives”. Journal of Molecular Structure, 1081, 85-95, 2015.
37. [37] Kumar S, Sharma N, Maurya I K, Bhasin AKK, Wangoo N, Brandao P, Felix V, Bhasin KK, Sharma RK. “Facile synthesis, structural evaluation, antimicrobial activity and synergistic effects of novel imidazo [1,2-a]pyridine based organoselenium compounds”. European Journal of Medicinal Chemistry, 123, 916-924, 2016.
38. [38] El-Gohary NS, Gabr MT, Shaaban MI. “Synthesis, molecular modeling and biological evaluation of new pyrazolo [3,4-b]pyridine analogs as potential antimicrobial, antiquorum-sensing and anticancer agents”. Bioorganic Chemistry, 89, 102976, 2019.
39. [39] Azzam RA, Elsayed RE, Elgemei GH. “Design and Synthesis of a New Class of Pyridine-Based N-Sulfonamides Exhibiting Antiviral, Antimicrobial, and Enzyme Inhibition Characteristics”. ACS Omega, 5(40), 26182-26194, 2020.
40. [40] Milosevic MD, Marinkovic AD, Petrovic P, Klaus A, Nikolic MG, Prlainovic NZ, Cvijetic IN. “Synthesis, characterization and SAR studies of bis(imino)pyridines as antioxidants, acetylcholinesterase inhibitors and antimicrobial agents”. Bioorganic Chemistry, 102, 104073, 2020.
41. [41] Kamat V, Santosh R, Poojary B, Nayak SP, Kumar BK, Sankaranarayanan M, Faheem Khanapure S, Barretto DA, Vootla SK. “Pyridine- and Thiazole-Based Hydrazides with Promising Anti-inflammatory and Antimicrobial Activities along with Their In Silico Studies”. ACS Omega, 5(39), 25228-25239, 2020.
42. [42] Ali I, Burki S, El-Haj B M, Shafiullah Parveen S, Nadeem HS, Nadeem S, Shah MR. “Synthesis and characterization of pyridine-based organic salts: Their antibacterial, antibiofilm and wound healing activities”. Bioorganic Chemistry, 100, 103937, 2020.
43. [43] Radwan MAA, Alshubramy MA, Abdel-Motaal M, Hemdan BA, El-Kady DS. “Synthesis, molecular docking and antimicrobial activity of new fused pyrimidine and pyridine derivatives”. Bioorganic Chemistry, 96, 103516, 2020.
44. [44] Mamedov I, Naghiyev F, Maharramov A, Uwangue O, Farewell A, Sunnerhagen P, Erdelyi M. “Antibacterial activity of 2-amino-3-cyanopyridine derivatives”. Mendeleev Communications, 30(4), 498-499, 2020.
45. [45] Gangjee A, Namjoshi OA, Yu J, Ihnat MA, Thorpe JE, Bailey-Downs L C. N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo [2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents”. Bioorganic & Medicinal Chemistry, 21(5), 1312-23, 2013.
46. [46] Chand K, Prasad S, Tiwari R K, Shirazi AN, Kumar S, Parang K, Sharma S K. “Synthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives”. Bioorganic Chemistry, 53, 75-82, 2014.
47. [47] Hu H, Wu J, Ao M, Zhou X, Li B, Cui Z, Wu T, Wang L, Xue, Y, Wu Z, Fang M. “Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: Novel potential CDK9 inhibitors”. Bioorganic Chemistry, 102, 104064, 2020.
48. [48] Yang H, Li Q, Su M, Luo F, Liu Y, Wang D, Fan Y. “Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition”. Bioorganic & Medicinal Chemistry, 46, 116346, 2021.
49. [49] Ye Q, Fu C, Li J. “Studying the Binding Modes of Novel 2-Aminopyridine Derivatives as Effective and Selective c-Met Kinase Type 1 Inhibitors Using Molecular Modeling Approaches”. Molecules, 26(52), 1-18, 2020.
50. [50] Miranda PO, Cubitt B, Jacob N T, Janda K D, de la Torre, J C “Mining a Krohnke Pyridine Library for Anti-Arenavirus Activity”. ACS Infectious Diseases, 4(5), 815-824, 2018.
51. [51] Wang G, Wan J, Hu Y, Wu X, Prhavc M, Dyatkina N, Rajwanshi V K, Smith D B, Jekle A, Kinkade A, Symons J A, Jin Z, Deval J, Zhang Q, Tam Y, Chanda S, Blatt L, Beigelman L. “Synthesis and Anti-Influenza Activity of Pyridine, Pyridazine, and Pyrimidine C-Nucleosides as Favipiravir (T-705) Analogues”. Journal of Medicinal Chemistry, 59(10), 4611-24, 2016.
52. [52] de Candia M, Fiorella F, Lopopolo G, Carotti A, Romano M R, Lograno M D, Martel S, Carrupt P A, Belviso BD, Caliandro R, Altomare C. “Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl)pyridine at the P1 position with potent anticoagulant activity”. Journal of Medicinal Chemistry, 56(21), 8696-711, 2013.
53. [53] Kang S, Kim RY, Seo MJ, Lee S, Kim YM, Seo M, Seo JJ, Ko Y, Choi I, Jang J, Nam J, Park S, Kang H, Kim HJ, Kim J, Ahn S, Pethe K, Nam K, No Z, Kim J. “Lead optimization of a novel series of imidazo [1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent”. Journal of Medicinal Chemistry, 57(12), 5293-305, 2014.
54. [54] Tantry S J, Markad SD, Shinde V, Bhat J, Balakrishnan G, Gupt, AK, Ambady A, Raichurkar A, Kedari C, Sharma S, Mudugal NV, Narayan A, Naveen Kumar CN. Nanduri R, Bharath S, Reddy J, Panduga V, Prabhakar K R, Kandaswamy K, Saralaya R, Kaur P, Dinesh N, Guptha S, Rich K, Murray D, Plant H, Ashton H, Plant D, Walsh J, Alcock P, Naylor K, Collier M, Whiteaker J, McLaughlin R E, Mallya M, Panda M, Rudrapatna S, Ramachandran V, Shandil R, Sambandamurthy VK, Mdluli K, Cooper CB, Rubin H, Yano T, Iyer P, Narayanan S, Kavanagh S, Mukherjee K, Balasubramanian V, Hosagrahara VP, Solapure S, Ravishankar S, & Hameed P S. “Discovery of Imidazo [1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis”. Journal of Medicinal Chemistry, 60(4), 1379-1399, 2017.
55. [55] Sagar SR, Singh D P, Das R D, Panchal NB, Sudarsanam V, Nivsarkar M, Vasu KK “Investigations on substituted (2-aminothiazol-5-yl)(imidazo [1,2-a]pyridin-3-yl)methanones for the treatment of Alzheimer's disease”. Bioorganic & Medicinal Chemistry, 36, 116091, 2021.
56. [56] Zarei S, Shafiei M, Firouzi M, Firoozpour L, Divsalar K, Asadipour A, Akbarzadeh T, Foroumadi A. “Design, synthesis and biological assessment of new 1-benzyl-4-((4-oxoquinazolin-3(4H)-yl)methyl) pyridin-1-ium derivatives (BOPs) as potential dual inhibitors of acetylcholinesterase and butyrylcholinesterase”. Heliyon, 7(4), e06683, 2021.
57. [57] Chiacchio MA, Iannazzo D, Romeo R, Giofrè SV, Legnani L. “Pyridine and pyrimidine derivatives as privileged scaffolds in biologically active agents” Current Medicinal Chemistry, 26(40), 7166-7195, 2019.
58. [58] Lackey HH, Chen Z, Harris JM, Peterson EM, Heemstra JM. “Single-molecule kinetics show DNA pyrimidine content strongly affects RNA: DNA and TNA: DNA heteroduplex dissociation rates”. ACS Synthetic Biology, 9(2), 249-253, 2020.
59. [59] Martina M G, Giannessi L, Radi M. “Multicomponent Synthesis of Purines and Pyrimidines: From the Origin of Life to New Sustainable Approaches for Drug‐Discovery Applications”. European Journal of Organic Chemistry, 26(2), e202201288, 2022.
60. [60] Nassar E, El Badry YA, Eltoukhy A M M “Synthesis and antiproliferative activity of 1-(4-(1H-Indol-3-Yl)-6-(4-Methoxyphenyl)Pyrimidin-2-yl)Hydrazine and ıts pyrazolo pyrimidine derivatives”. Medicinal Chemistry, 06(04), 2016.
61. [61] Kamal A, Reddy J S, Ramaiah MJ, Dastagiri D, Bharathi EV, Prem Sagar MV, Pushpavalli S N C V L, Ray P, Pal-Bhadra M. “Design, synthesis and biological evaluation of imidazopyridine/pyrimidine-chalcone derivatives as potential anticancer agents”. Medicinal Chemistry Communications, 1(5), 355, 2010.
62. [62] Mathew B, Suresh J, Anbazghagan S, Paulraj J, Krishnan GK. Krishnan “Heteroaryl chalcones: Mini review about their therapeutic voyage”. Biomedicine & Preventive Nutrition, 4(3), 451-458, 2014.
63. [63] Brown KK, Spinelli JB, Asara JM, Toker A. “Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer”. Cancer Discovery, 7(4), 391-399, 2017.
64. [64] Hassan, A S, Mady, M F, Awad, H M, Hafez, T S. “Synthesis and antitumor activity of some new pyrazolo [1,5- a]pyrimidines”. Chinese Chemical Letters, 28(2), 388-393, 2017.
65. [65] Khalaf HS, Tolan HEM, Radwan MAA, Mohamed AM, Awad HM, El-Sayed W A. “Design, synthesis and anticancer activity of novel pyrimidine and pyrimidine-thiadiazole hybrid glycosides”. Nucleosides Nucleotides Nucleic Acids, 39(7), 1036-1056, 2020.
66. [66] Banda V, Jitender DG, Santhosh K G, Sambasiva RP, Chavva K, Rajesh P, Venkateswara RJ, Banda N. “Studies on Synthesis of Novel Pyrido [2,3‐d] pyrimidine Derivatives and Their Anticancer Activity”. Journal of Heterocyclic Chemistry, 55(11), 2538-2544, 2018.
67. [67] Padarthi P K, Sridhar S, Jagatheesh K, Namasivayam E. “Synthesis and Biological Activity of Imidazole Derived Chalcones and It’s Pyrimidines”. International journal of Research in Ayurveda & Pharmacy, 4(3), 355-362, 2013.
68. [68] Hassan MM, Farouk O. “Synthesis and antimicrobial evaluation of some functionalized heterocycles derived from novel quinolinyl chalcone”. Journal of Heterocyclic Chemistry, 54(6), 3133-3142, 2017.
69. [69] Gaikwad SS, Suryawanshi VS, Lohar KS, Jadhav DV, Shinde ND. “Synthesis and biological activity of some 3,4‐Dihydro‐4‐(4‐substituted aryl)‐6‐(naptho [2,1‐b]furan‐2‐yl pyrimidine‐2(1H)‐one Derivatives”. Journal of Chemistry, 9(1), 175-180, 2011.
70. [70] Hussein AHM, Gad-Elkareem MAM, El-Adasy A.-BAAM, Khames AA, Othman I.M.M. “β-Oxoanilides in heterocyclic synthesis: synthesis and antimicrobial activity of pyridines, pyrans, pyrimidines and azolo, azinopyrimidines ıncorporating antipyrine moiety”. International Journal of Organic Chemistry, 2(04), 341-351, 2012.
71. [71] Anupama B. Singh “Synthesis of pharmacologically ımportant some novel pyrimidine and chalcone moieties containing s-triazines”. American Chemical Science Journal, 8(2), 1-7, 2015.
72. [72] Perlikova P, Hocek M. “Pyrrolo [2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides”. Medicinal Research Reviews, 37(6), 1429-1460, 2017.
73. [73] Shen J, Meng X. “Selective synthesis of pyrimidines from cinnamyl alcohols and amidines using the heterogeneous OMS-2 catalyst”. Catalysis Communications, 138, 105846, 2020.
74. [74] Radwan M A, Alshubramy M A, Abdel-Motaal M, Hemdan BA, El-Kady DS. “Synthesis, molecular docking and antimicrobial activity of new fused pyrimidine and pyridine derivatives”. Bioorganic Chemistry, 96, 103516, 2020.
75. [75] Jian X E, Yang F, Jiang CS, You W W, Zhao PL. “Synthesis and biological evaluation of novel pyrazolo [3,4-b]pyridines as cis-restricted combretastatin A-4 analogues”. Bioorganic & Medicinal Chemistry Letters, 30(8), 127025, 2020.
76. [76] Hatti I, Sujana O, Nookaraju M, Suresh J, Aparna Seetharam K, Raju R R. “Rational design, synthesis, and anticancer evaluation of pyridine and substituted aryl linked 1,3,4-oxadiazole derivatives”. Results in Chemistry, 11, 101755, 2024.
77. [77] Jami PK, Battula S R, Sandhya J, Parimi UD. “Design, synthesis and biological evaluation of amide derivatives of isoxazole-imidazo [1,2-a]pyridine as anticancer agents”. Chemical Data Collections, 44, 101001, 2023.
78. [78] Zhang J, Dai J, Lan X, Zhao Y, Yang F, Zhang H, Tang S, Liang G, Wang X, Tang Q. “Synthesis, bioevaluation and molecular dynamics of pyrrolo-pyridine benzamide derivatives as potential antitumor agents in vitro and in vivo”. European Journal of Medicinal Chemistry, 233, 114215, 2022.
79. [79] Khan S, Ullah H, Rahim F, Hussain R, Khan Y, Khan MS, Iqbal R, Ali B, Albeshr MF. “Synthesis, biological evaluation and molecular docking study of pyrimidine based thiazolidinone derivatives as potential anti-urease and anti-cancer agents”. Journal of Saudi Chemical Society, 27(4), 101688, 2023.
80. [80] Wang S, Zhang RH, Zhang H, Wang YC, Yang D, Zhao YL, Yan G Y, Xu G B, Guan HY, Zhou YH, Cui DB, Liu T, Li YJ, Liao SG, Zhou M. “Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities”. European Journal of Medicinal Chemistry, 222, 113573, 2021.
81. [81] Reddy BS, Rao GPC, Devi ER, Prasad KRS, Nalla S. “Synthesis and biological evaluation of 1,2,3-triazole incorporated pyridin-4-yl)-1H-1,2,4-triazol-3-yl)pyrimidine derivatives as anticancer agents”. Results in Chemistry, 8, 101598, 2024.
82. [82] Dashyan SS, Babaev E V, Ayvazyan AG, Mamyan SS, Paronikyan EG, Nikoghosyan TA, Hunanyan L S, Paronikyan R G. “Synthesis, evaluation of biological activity and SAR of new thioalkyl derivatives of pyridine”. Bioorganic Chemistry, 148, 107435, 2024.
83. [83] Desai NC, Vaja DV, Monapara JD, Manga V, Vani T. “Synthesis, biological evaluation, and molecular docking studies of novel pyrazole, pyrazoline‐clubbed pyridine as potential antimicrobial agents”. Journal of Heterocyclic Chemistry, 58(3), 737-750, 2021.
84. [84] Borthakur SK, Kalita PK, Borthakur S.”Synthesis and antifungal activities of 3,5‐diphenyl‐7‐amino‐ [1,3]‐thiazolo [3,2‐a]pyrimidine‐6‐nitrile derivatives”. Journal of Heterocyclic Chemistry, 57(3), 1261-1265, 2020.
85. [85] Hari KN, Poojary B, Chandrasehar G. “Design, synthesis and evaluation of new alkylated pyrimidine derivatives as antibacterial agents”. Results in Chemistry, 4, 100676, 2022.
86. [86] Elsayed MA, Elsayed AM, Sroor FM. “Novel biologically active pyridine derivatives: Synthesis, structure characterization, in vitro antimicrobial evaluation and structure-activity relationship”. Medicinal Chemistry Research, 33(3), 476-491, 2024.
87. [87] Nerkar AU. “Use of Pyrimidine and Its Derivative in Pharmaceuticals: A Review”. Journal of Advanced Chemical Sciences, 7(2), 729-732, 2021.
88. [88] Roopan SM, Sompalle R. “Synthetic chemistry of pyrimidines and fused pyrimidines: A review”. Synthetic Communications, 46(8), 645-672, 2016.
89. [89] Kerru N, Gummidi L, Maddila S, Gangu KK, Jonnalagadda SB “A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications”. Molecules, 25(8), 2020.
90. [90] Pinheiro S, Pinheiro EMC, Muri EMF, Pessôa J C, Cadorini MA, Greco SJ. “Biological activities of [1,2,4]triazolo [1,5-a]pyrimidines and analogs”. Medicinal Chemistry Research, 29(10), 1751-1776, 2020.
91. [91] Dai XJ, Xue LP, Ji SK, Zhou Y, Gao Y, Zheng YC, Liu HM, Liu HM. “Triazole-fused pyrimidines in target-based anticancer drug discovery”. European Journal of Medicinal Chemistry, 249, 115101, 2023.
92. [92] Oukoloff K, Lucero B, Francisco KR, Brunden K R, Ballatore C. “1,2,4-Triazolo [1,5-a]pyrimidines in drug design”. European Journal of Medicinal Chemistry, 165, 332-346, 2019.
93. [93] Frydrych A, Jurowski K. “Toxicity of minoxidil-Comprehensive in silico prediction of main toxicity endpoints: Acute toxicity, irritation of skin and eye, genetic toxicity, health effect, cardiotoxicity and endocrine system disruption”. Chemico-Biological Interactions, 393, 110951, 2024.
94. [94] Mohammed SM, Masry AA, Moustafa AH, El-Sayed HA, Gad EM, Morsy HA. “K2CO3-nanoparticles catalyzed the synthesis of 3-arylidine imidazo [1,2-c]pyrimidine candidates” Cytotoxic activity and docking study”. Synthetic Communications, 53(16), 1319-1332, 2023.
95. [95] Burgos CF, Sanchez C, Sepulveda C, Fuentes E, Palomo I, Alarcon M. “Anti-aggregation effect on platelets of Indiplon a hypnotic sedative non-benzodiazepine drug”. Biomed Pharmacother, 111, 378-385, 2019.
96. [96] Piccirillo G, Aroso R, Baptista JA, Silva GJ, Pereira MM, Canotilho J, Ermelinda SEM. “Trimethoprim-Based multicomponent solid Systems: Mechanochemical Screening, characterization and antibacterial activity assessment”. International Journal of Pharmaceutics, 661, 124416, 2024.
97. [97] Skolnick P. “Anxioselective anxiolytics: on a quest for the Holy Grail” Trends in Pharmacological Sciences, 33(11), 611-20, 2012.
98. [98] Oktay AN, Polli JE. “Comparison of a single pharmaceutical surfactant versus intestinal biorelevant media for etravirine dissolution: Role and impact of micelle diffusivity”. International Journal of Pharmaceutics, 624, 122015, 2022.
99. [99] Muftakhov MV, Shchukin PV, Khatymov R V. “Thymidine and stavudine molecules in reactions with low-energy electrons”. Radiation Physics and Chemistry, 184, 109464, 2021.
100. [100] Bachir M, Guglielmetti L, Tunesi S, Billard-Pomares T, Chiesi S, Jaffre J, Langris H, Pourcher V, Schramm F, Lemaitre N, Robert J. “Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France”. Journal of Infection, 85(1), 24-30, 2022.
101. [101] Wang X, Cheng G, Liang X, Yang J, Deng A, Chen D, Liu C, Gao Y, Li J. “Toxic Epidermal Necrolysis Observed in a Patient With the HLA-B*1502 Treated With Levofloxacin”. Clinical Therapeutics, 46(12), 1082-1085, 2024.
102. [102] Neuner S, Gelbrich T, Wurst K, Spreitz J, Nerdinger S, Griesser UJ, Stefinovic M, Schottenberger H. “Iclaprim mesylate displaying a hydrogen-bonded molecular tape”. Acta Crystallographica Section E Crystallographic Communications, 79(1), 24-27, 2023.
103. [103] Hoseyni K, Sepehri B, Irani M. “Discovery of new Glyoxalase I inhibitors by repurposing of FDA-approved drugs: An in silico study”. Journal of Molecular Structure, 1312, 138522, 2024.
104. [104] Fiste O, Mavrothalassitis E, Apostolidou K, Trika C, Liontos M, Koutsoukos K, Kaparelou M, Dimitrakakis C, Gavriatopoulou MA, Dimopoulos MA, Zagouri F “Cardiovascular complications of ribociclib in breast cancer patients”. Critical Reviews in Oncology/Hematology, 196, 104296, 2024.
105. [105] Sedrak MS, Lee MK, Ji J, Satele DV, Freedman RA, Poorvu PD, O'Connor T, Williams GR, Hopkins JO, Muss HB, Cohen HJ, Partridge AH, Carey LA, Chow SL, Subbiah N, Le-Rademacher A, Jatoi A. “Palbociclib in adults aged 70 years and older with advanced breast cancer: A phase 2 multicenter trial (Alliance A171601)”. Journal of Geriatric Oncology, 15(6), 101813, 2024.
106. [106] Sakaguchi K, Naito T, Hoshikawa K, Miyadera Y, Tanaka H, Nakatsugawa E, Furuta T, Sugimoto K, Kawakami J. “Characterization of plasma vonoprazan and CYP3A activity using its endogenous marker and genetic variants in patients with digestive system disorders”. Drug Metabolism and Pharmacokinetics, 58, 101027, 2024.
107. [107] Alzhrani RM, Almalki AH, Alosaimi ME, Algarni MA, Abduljabbar MH, Aldawsari MF, Alturki MS, Alsulami FT, Abdelazim AH “Spectrofluorometric determination of futibatinib in human plasma and pharmaceutical formulations”. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 320, 124543, 2024.
108. [108] Nehra B, Kumar M, Singh S, Chawla PA. “Olutasidenib: A ray of hope in the treatment of acute myeloid leukaemia”. Health Sciences Review, 7, 100100, 2023.
109. [109] Bacharach J, Brubaker JW, Evans DG, Lu F, Odani-Kawabata N, Yamabe T, Wirta DL. “Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)”. American Journal of Ophthalmology, 263, 23-34, 2024.
110. [110] Mashau R C, Meiring S T, Quan VC, Nel J, Greene G S, Garcia A, Menezes C, Reddy D L, Venter M, Stacey S, Madua, M, Boretti L, Harrison TS, Meintjes G, Shroufi A, Trivino-Duran L, Black J, Govender N P. “Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study”. Lancet Infect Dis, 22(9), 1365-1373, 2022.
111. [111] Zarenezhad E, Farjam M, Iraji A. “Synthesis and biological activity of pyrimidines-containing hybrids: Focusing on pharmacological application” Journal of Molecular Structure 1230, 129833, 2021.
112. [112] Uppuluri CT, Ravi PR, Dalvi AV. “Design and evaluation of thermo-responsive nasal in situ gelling system dispersed with piribedil loaded lecithin-chitosan hybrid nanoparticles for improved brain availability”. Neuropharmacology, 201, 108832, 2021.